

MyoKardia (USA): Constituent Deletion

Changes in FTSE RAFI™ Index Series

17 November 2020

Following the completion of the tender offer for MyoKardia (USA, constituent) by Bristol Myers Squibb, please see details of affected indexes and effective dates below:

Index	Effective From Start of Trading
FTSE RAFI US 1500 Mid Small Index	20 November 2020
FTSE RAFI US 1500 Mid Small Index - QSR	20 November 2020

*Due to the absence of an active market MyoKardia will be removed at the tender offer terms of \$225.00 per share held.

For further information please contact FTSE Russell Client Services at info@ftserussell.com or call:

Australia	+1800 653 680
Hong Kong	+852 2164 3333
Japan	+81 3 4563 6346
London	+44 (0) 20 7866 1810
New York	+1866 551 0617

Alternatively please visit our website at www.ftserussell.com

[Terms of Use](#) | Copyright © 2020 FTSE Russell